Sign Out
No drug interaction studies have been conducted at the moment. The following information is based on results from in vitro studies and physiologically based pharmacokinetic (PBPK) simulations. Caution is advised if these drugs are given concomitantly.
Effect of other medications on pimitespib: P-gp and BCRP inhibitors or inducers: Pimitespib is a substrate of P-gp and BCRP (in vitro). P-gp and BCRP inhibitors or inducers may alter the concentration and activity of pimitespib.
Effect of pimitespib on other medications: CYP3A substrates: Pimitespib has a potential to time-dependently inhibit CYP3A (in vitro) and PBPK simulations suggested that midazolam concentration may be increased when used in combination of pimitespib.
MATE1 and MATE2-K substrates: Pimitespib has a potential to inhibit MATE1 and MATE2-K (in vitro) and PBPK simulations suggested that metformin concentration may be increased when used in combination of pimitespib.
P-gp, BCRP, and OATP1B1 substrates: Pimitespib has a potential to inhibit P-gp, BCRP, and OATP1B1 (in vitro). P-gp, BCRP, and OATP1B1 substrates concentration may be increased when used in combination of pimitespib.
Continue with Google